In summary, the findings of this study demonstrate that, within a subset of EGFR-mutated NSCLC patients with LM, EGFR gene amplification is more likely to occur at the LM stage than at initial diagnosis. This evidence concerns the gene EGFR and non-small cell lung carcinoma.